Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yvonne Ka Yin Kwok has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Kwong Wai Choy

    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, China

    9 shared publications
  • Tak Yeung Leung

    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China

    5 shared publications
  • Huilin Wang

    Department of Center Laboratory, Maternal-Fetal Medicine Institute, Shenzhen Key Laboratory of Birth Defects Research, Birth Defects Prevention Research and Transformation Team, Baoan Maternity and Child Health Hospital Affiliated to Jinan University School of Medicine, Shenzhen, China

    3 shared publications
  • Matthew Hoi Kin Chau

    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong , Hong Kong SAR

    3 shared publications
  • Ye Cao

    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, China

    3 shared publications
  • Angel Hoi Wan Kwan

    Department of Obstetrics and Gynaecology The Chinese University of Hong Kong Hong Kong SAR China

    2 shared publications

Latest Publications

  • Open Access

    Cell‐free DNA test for fetal chromosomal abnormalities in multiple pregnancies

    by Angel H. W. Kwan, Maria Mar Gil, Shuwen Xue, Yvonne K. Y. Kwok, Doris Lau, Joanna Fung, Andrea Chan, Kwong Wai Choy, Tak Yeung Leung, Liona C. Poon

    Introduction: This study aimed to report the screening performance of cell‐free DNA (cfDNA) testing for chromosomal abnormalities in twins, triplets, and vanishing twin pregnancies.Material and Methods: Data were obtained from pregnant women with a multiple pregnancy or a vanishing twin pregnancy at ≥10 weeks’ gestation who requested self‐financed cfDNA testing between May 2015 and December 2021. Those that had positive screening results had diagnostic confirmatory procedures after counseling and consent. The performance of screening of the cfDNA test was determined by calculating confirmation rate and combined false‐positive rate (cFPR).Results: Data from 292 women were included after exclusion of those lost to follow‐up, with no‐result on cfDNA testing, or had reductions. Of the 292 pregnancies, 10 (3.4%) were triplets, including no cases of trisomy 21 and trisomy 18; 249 (85.3%) were twins, including 3 cases of trisomy 21 and no cases of trisomy 18 and 13; and 33 (11.3%) were vanishing twins, including 3 cases of trisomy 21 and 1 case of trisomy 18. The median (IQR) maternal age was 34 years (31–37). For triplet pregnancies, the initial no‐result rate was 10.3% (95% confidence interval [CI] 3.6–26.4), all with results after redraw. For twin pregnancies, the initial no‐result rate was 12.9% (95% CI 9.6–17.0), and the no‐result rate after redraw was 1.6% (95% CI 0.7–3.6). For vanishing twins, there were no cases with no‐result. All triplets had low‐risk cfDNA results. The confirmation rate for trisomy 21 was 100% with a FPR at 0% due to the small number of positive cases for twins. For vanishing twins, one high‐risk case for trisomy 21 and the only high‐risk case for trisomy 18 were confirmed with a cFPR of 8.3% (n = 2/24; 95% CI 2.3–25.9).Conclusions: cfDNA testing in twin pregnancies has sufficient screening performance for trisomy 21 but the number of affected cases for other conditions is limited to draw any meaningful conclusion. The use of cfDNA testing in triplet pregnancies and vanishing twins remains an area for further research.


  • Open Access

    Amniotic fluid gamma-glutamyl transferase for prediction of biliary atresia in cases of non-visualisation of the fetal gallbladder: a retrospective study using a validated analytical platform and local reference range

    by Tommy Yt Cheung, Natalie Kl Wong, Daljit Singh Sahota, Shreenidhi Ranganatha Subramaniam, Sl Lau, X Zhu, Wt Lui, Edwin Kw Chan, Yvonne Ky Kwok, Kw Choy, et al.

    Hong Kong Med J 2024;30:Epub 5 Jun 2024 https://doi.org/10.12809/hkmj2210567 © Hong Kong Academy of Medicine.


  • Open Access

    Genome-Wide Cell-Free DNA Test for Fetal Chromosomal Abnormalities and Variants: Unrestricted Versus Restricted Reporting

    by Angel H. W. Kwan, Xiaofan Zhu, Maria Mar Gil, Yvonne K. Y. Kwok, Isabella Y. M. Wah, Annie S. Y. Hui, Yuen-Ha Ting, Kwok-Ming Law, Doris Lau, Shuwen Xue, et al.

    This study aimed to compare the screening performance of genome-wide cfDNA testing for chromosomal abnormalities between two periods where additional findings were reported and not reported. Data were obtained from consecutive pregnant women with a singleton pregnancy at ≥10 weeks who requested cfDNA testing during 2015–2019. The performance of screening of the cfDNA test was determined by calculating the concordance rate, detection rate, and false-positive rate. Data from 3981 women were included. The no-result rates were similar between the two reporting periods (2.04% vs. 2.08%). Concordance rates for trisomy 21 and 18 were 100% and 100%, respectively. There were two cases tested high risk for trisomy 13, with a concordance rate of 0%. In total, 12 cases were high risk for any sex chromosome aneuploidy with an overall concordance of 75%, and 15 cases tested high risk for any rare autosomal trisomy, with a 13.3% concordance rate. The detection rates for trisomy 21 and 18 were 100% and 100%, respectively. For any SCA, the detection rate was 90%. For the two reporting periods, the combined false-positive rates were 0.93% and 0.17%, which were significantly different (p = 0.002). Restricting the reporting of additional findings from genome-wide cfDNA analysis has reduced the false-positive rate but without a reduction in the no-result rate.


  • Open Access

    Clinical Significance of Non-Invasive Prenatal Screening for Trisomy 7: Cohort Study and Literature Review

    by Xiaofan Zhu, Doris Yuk Man Lam, Matthew Hoi Kin Chau, Shuwen Xue, Peng Dai, Ganye Zhao, Ye Cao, Sunny Wai Hung Cheung, Yvonne Ka Yin Kwok, Kwong Wai Choy, et al.

    Trisomy 7 is the most frequently observed type of rare autosomal trisomies in genome-wide non-invasive prenatal screening (NIPS). Currently, the clinical significance of trisomy 7 NIPS-positive results is still unknown. We reviewed two independent cohorts from two laboratories where similar NIPS metrics were applied. A total of 70,441 singleton cases who underwent genome-wide NIPS were analyzed, among which 39 pregnancies were positive for trisomy 7, yielding a screen-positive rate of 0.055% (39/70,441). There were 28 cases with invasive testing results available; the positive predictive value (PPV) was 3.6% (1/28). We then searched the published NIPS studies to generate a large cohort of 437,873 pregnancies and identified 247 cases (0.056%) that were screened positive for trisomy 7. The overall PPV was 3.4% (4/118) in the combined data. The presence of uniparental disomy 7 was not detected in the NIPS trisomy 7-positive pregnancies with normal fetal karyotype. Among the 85 cases with pregnancy outcome available in combined data, 88.2% were normal live births, 14.1% had intrauterine growth restriction, preterm birth or low birth weight, 3.5% presented with ultrasound abnormality, and no fetal loss was observed. Our data provide valuable information for counseling and management of trisomy 7-positive NIPS pregnancies.


  • Low-pass genome sequencing: a validated method in clinical cytogenetics

    by Matthew Hoi Kin Chau, Huilin Wang, Yunli Lai, Yanyan Zhang, Fuben Xu, Yanqing Tang, Yanfang Wang, Zihan Chen, Tak Yeung Leung, Jacqueline Pui Wah Chung, et al.

    Clinically significant copy-number variants (CNVs) known to cause human diseases are routinely detected by chromosomal microarray analysis (CMA). Recently, genome sequencing (GS) has been introduced for CNV analysis; however, sequencing depth (determined by sequencing read-length and read-amount) is a variable parameter across different laboratories. Variating sequencing depths affect the CNV detection resolution and also make it difficult for cross-laboratory referencing or comparison. In this study, by using data from 50 samples with high read-depth GS (30×) and the reported clinically significant CNVs, we first demonstrated the optimal read-amount and the most cost-effective read-length for CNV analysis to be 15 million reads and single-end 50 bp (equivalent to a read-depth of 0.25-fold), respectively. In addition, we showed that CNVs at mosaic levels as low as 30% are readily detected, furthermore, CNVs larger than 2.5 Mb are also detectable at mosaic levels as low as 20%. Herein, by conducting a retrospective back-to-back comparison study of low-pass GS versus routine CMA for 532 prenatal, miscarriage, and postnatal cases, the overall diagnostic yield was 22.4% (119/532) for CMA and 23.1% (123/532) for low-pass GS. Thus, the overall relative improvement of the diagnostic yield by low-pass GS versus CMA was ~ 3.4% (4/119). Identification of cryptic and clinically significant CNVs among prenatal, miscarriage, and postnatal cases demonstrated that CNV detection at higher resolutions is warranted for clinical diagnosis regardless of referral indications. Overall, our study supports low-pass GS as the first-tier genetic test for molecular cytogenetic testing.


  • Characteristics and mode of inheritance of pathogenic copy number variants in prenatal diagnosis

    by Matthew Hoi Kin Chau, Ye Cao, Yvonne Ka Yin Kwok, Samantha Chan, Yiu Man Chan, Huilin Wang, Zhenjun Yang, Hoi Kin Wong, Tak Yeung Leung, Kwong Wai Choy


  • A prospective study of non-invasive preimplantation genetic testing for aneuploidies (NiPGT-A) using next-generation sequencing (NGS) on spent culture media (SCM)

    by Queenie S. Y. Yeung, Ying Xin Zhang, Jacqueline P. W. Chung, Wai Ting Lui, Yvonne K. Y. Kwok, Baoheng Gui, Grace W. S. Kong, Ye Cao, Tin Chiu Li, Kwong Wai Choy

    Purpose This study was to evaluate if spent culture media (SCM) of embryos could be used as a non-invasive tool to achieve aneuploidy screening. Ploidy calls, as well as concordance rates between PGT-A results from trophectoderm (TE) and SCM, were compared. Clinical outcomes of single euploid transfers were also evaluated. Methods The study was conducted from March 2017 to June 2018 in a university-based ART center. SCM of day 3 to the day(s) of TE biopsy of all biopsied blastocysts were collected for testing. PGT-A results of SCM were compared with the standard results of TE, with clinical relevance and outcomes examined. Results NiPGT-A using SCM gave a sensitivity of 81.6%, specificity of 48.3%, positive predictive value of 82.6%, and negative predictive value of 46.7% in ploidy calling. The concordance rates for autosomes and sex determination were 62.1% and 82.4%, respectively. There were 14 single embryo transfer cycles of euploids as determined by TE biopsy. Clinical outcomes not only confirmed 3 false positive results from SCM but also reflected the true ploidy status of the transferred embryo in one case. If ploidy calls were dichotomized without mosaic embryos, the sensitivity and NPV would increase to 91.0% and 66.7% (p = 0.60 and p = 0.25), respectively. Conclusions Cell-free DNA found in SCM could provide ploidy information of an embryo as in PGT-A from its TE. Given its potential to reflect the comprehensive chromosomal profile of the whole embryo, more research based on clinical outcomes is required to determine if SCM could be a reliable selection tool in PGT-A.


  • Chromosome copy number variants in fetuses with syndromic malformations

    by Huilin Wang, Matthew Hoi Kin Chau, Ye Cao, Ka Yin Kwok, Kwong Wai Choy

    Chromosome copy number variants (CNVs; gains and losses of DNA sequences >1 kb) are wide‐spread throughout the genome of healthy individuals. Laboratory studies show that a subset of CNVs are pathogenic, and not only can be responsible for the pathogenesis of major birth defects and cancer, but are also associated with neurodevelopmental disorders at birth. The characteristics of the pathogenic microdeletions and microduplications are important for both clinical implications and genetic counselling regarding test selection for prenatal screening and diagnosis. Unfortunately, our knowledge of the phenotypic effects of most CNV is still minimal, leading to the classification of many CNVs as “genomic imbalances of unknown clinical significance”. Microdeletions and microduplications can occur in all pregnancies and the spectrum of pathogenic CNVs in fetuses with syndromic malformations is not well studied. This review summarizes our current understanding of CNVs, the common detection methods, and the characteristics of pathogenic CNVs identified in fetuses with syndromic malformations. Birth Defects Research 109:725–733, 2017.


  • Validation of a robust PCR-based assay for quantifying fragile X CGG repeats

    by Yvonne K. Kwok, Kit Man Wong, Fai Man Lo, Grace Wing Shan Kong, J. Kent Moore, Shaoping Wu, Stephen T.S. Lam, Mack Schermer, Tak Yeung Leung, Kwong Wai Choy


  • BACs-on-beads: a new robust and rapid detection method for prenatal diagnosis

    by Richard Kwong Wai Choy, Ying Chen, Xiao-Fang Sun, Yvonne Ka Yin Kwok, Tak Yeung Leung

    Karyotyping, the gold standard used for diagnosis of chromosomal abnormalities, is being progressively replaced by rapid aneuploidy testing (RAT) techniques such as quantitative fluorescence-PCR, FISH and multiplex ligation-dependent probe amplification for diagnosing the common aneuploidies or chromosomal microarray analysis for comprehensive genome-wide testing. However, due to technical limitations, current RATs are confined to the detection of common aneuploidies 13, 18, 21 and sex chromosomes. To overcome the limitations of RATs, a bacterial artificial chromosomes-on-beads (BoBs™) assay technology has been introduced for the detection of the common aneuploidies as well as specific microdeletion syndromes. The BoBs assay is a bead-based multiplex assay using polystyrene beads impregnated with two spectrally distinct infrared fluorochromes to create a liquid array of up to 100 unique spectral signatures that supports the analysis of that scale of simultaneous hybridization assays on a minute DNA sample. This review gives an overview on the collective experiences of BoBs applications in prenatal diagnosis.